| Discussion topic: |
| Safety of COVID-19 Vaccines |
| There will be two main presentations as follows: |
|
COVID-19 Vaccine Safety – Perspective from WHO’s Global Advisory Committee on Vaccine Safety COVID-19 Vaccine Safety – US experience |
| Discussion topic: |
| Vacunas contra el COVID: ¿Hay necesidad de refuerzos en vista de la aparición de nuevas variantes y la disminución de la inmunidad? |
| Session 4 (en español) |
|
Presidente: Professor Romina Libster, Fundación INFANT, Argentina y profesora del ADVAC Disertantes: Professor Celia Alpuche, Instituto Nacional de Salud Publica, Mexico Discusion: |
| Discussion topic: |
| COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity? |
| Session 3 : 17:00-19:00 - (english) |
|
Chair: Professor Anna Durbin, Johns Hopkins Bloomberg School of Public Health, USA and Member of the ADVAC Scientific Committee Presenters: Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK Booster versus 2+1 primary immunisation vaccination: Does it matter? Professor Stanley Plotkin, University of Pennsylvania, USA Correlates of Protection as Indicators for Third Doses of COVID Vaccines |
| Discussion topic: |
| Vaccins COVID - est-il nécessaire de procéder à des rappels compte tenu de l'émergence de variants et de la baisse de l'immunité dans le temps? |
| Session 2 : 14:00-16:00 - (en français) |
|
Président: Prof. Paul-Henri Lambert, Université de Genève et Membre du comité scientifique d’ADVAC Orateurs: Dre Christiane Eberhardt et Prof. Arnaud Didierlaurent, Université de Genève Pour quoi, pour qui et pour quand? La 3ème dose du vaccin COVID-19 en question ! |
| Discussion topic: |
| COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity? |
| Session 1 : 10:00-12:00 - (english) |
|
Chair: Dr Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland and Member of the ADVAC Scientific Committee Presenters: Dr Jerome Kim, International Vaccine Institute, Seoul, Republic of Korea |
| Discussion topic: |
| Will the success of mRNA vaccine development platforms for COVID-19 lead to new platforms for old vaccines? |
| There will be two main presentations as follows: |
|
The Immunological benefits of mRNA and potential applications Regulatory approaches: Issues and challenges, and questions to be asked by regulators Dr Martin Friede, WHO will chair the meeting. |
| Discussion topic: |
| The impact of COVID-19 on the immunization programmes and how to correct the situation. |
| Presenters: Dr Richard Mihigo, WHO Regional Office for Africa |
| Discussion topic: |
| Logistics of deployment of COVID vaccines on a global level - how vaccines will make it to the most vulnerable populations |
| Presenters: Professor Lisa Cooper, Johns Hopkins Bloomberg School of Public Health Dr Katherine O’Brien, WHO |
| Chairs: Professor Anna Durbin, John Hopkins Bloomberg School of Public Health Dr Emily Erbelding, NIAID/National Institutes of Health, USA. |
